Jason Rhodes

Co-Founder at Disarm Therapeutics, Inc.

Jason Rhodes

Jason Rhodes

Co-Founder at Disarm Therapeutics, Inc.

Overview
Career Highlights

FORUM Pharmaceuticals, Inc.
Epizyme, Inc.
Dyne Therapeutics, Inc.

RelSci Relationships

4354

Number of Boards

14

Birthday

1969

Age

52

Contact Data
Trying to get in touch with Jason Rhodes? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jason Rhodes likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Rodin Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Generation Bio Co.

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

President, Treasurer & Director at Q32 Bio, Inc.

Relationship likelihood: Strong

Co-Founder at Disarm Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Replimune Group, Inc.

Relationship likelihood: Strong

Founder at Generation Bio Co.

Relationship likelihood: Strong

Venture Partner at Atlas Venture, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Dyne Therapeutics, Inc.

Relationship likelihood: Strong

Executive Chairman at Synlogic, Inc.

Relationship likelihood: Strong

Paths to Jason Rhodes
Potential Connections via
Relationship Science
You
Jason Rhodes
Co-Founder at Disarm Therapeutics, Inc.
Education
MBA
Class of 1996

The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.

BA Unknown
Class of 1991

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Career History
Chairman
2017 - Current

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Co-Founder
2016 - Current

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.

Chairman
2016 - Current

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Boards & Committees
Director
Prior

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Political Donations
$5
2018

ActBlue is an online toolset that makes it easy for donors to connect with the candidates and causes they support. At ActBlue, the objective is to democratize power by putting powerful fundraising tools in the hands of grassroots donors across the United States.

$25
2018

ActBlue is an online toolset that makes it easy for donors to connect with the candidates and causes they support. At ActBlue, the objective is to democratize power by putting powerful fundraising tools in the hands of grassroots donors across the United States.

$50
2018

ActBlue is an online toolset that makes it easy for donors to connect with the candidates and causes they support. At ActBlue, the objective is to democratize power by putting powerful fundraising tools in the hands of grassroots donors across the United States.

Transactions
Details Hidden

Epizyme, Inc. issued USD Common Stock

Investments
Details Hidden

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Details Hidden

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Details Hidden

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jason Rhodes. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jason Rhodes's profile does not indicate a business or promotional relationship of any kind between RelSci and Jason Rhodes.